Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, Irvine
Disc Medicine, Inc
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Incyte Corporation
Constellation Pharmaceuticals
Chengdu Zenitar Biomedical Technology Co., Ltd
Ohio State University Comprehensive Cancer Center
AbbVie
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
University of Nebraska
University of Washington
Incyte Corporation
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Takeda
NS Pharma, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Novartis
Groupe Francophone des Myelodysplasies
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
Alliance for Clinical Trials in Oncology
Italfarmaco
Incyte Corporation
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Traws Pharma, Inc.
Baylor College of Medicine
Polyphor Ltd.
Memorial Sloan Kettering Cancer Center
Humanigen, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)